Roivant Sciences Ltd.
As of Oct 22, 2026, Roivant Sciences is in Stage 2, the uptrend phase, now in week 64 (since Jul 23, 2025). It closed at $37.45, 10.4% below its 52-week high and above its 200-day average, which is rising.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is ROIV early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ROIV among Biotechnology41st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …41 | ROIV | Stage 2 · wk 64 | 95 | +1.7% |
Roivant Sciences: quick answers
What stage is Roivant Sciences in?
As of Oct 22, 2026, Roivant Sciences (ROIV) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 23, 2025 and is in week 64. What the four stages mean
Is Roivant Sciences in an uptrend?
Yes. Roivant Sciences is in a Stage 2 uptrend. It trades 20.5% above its 200-day average, which is rising.
How far is Roivant Sciences from its 52-week high?
Roivant Sciences closed at $37.45 on Oct 22, 2026, 10.4% below its 52-week high of $41.81. Its 52-week low is $17.96.
How has Roivant Sciences performed over the past year?
As of Oct 22, 2026, Roivant Sciences is up 109.6% over the past year and up 70.8% so far in 2026.
Which sector and industry is Roivant Sciences in?
Roivant Sciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.